United StatesHHS would study fentanyl testing in hospital emergency departments
If enacted, HHS would study fentanyl testing for overdose patients and later guide hospitals on whether and how routine testing should be used.
What it does
HHS would study how often emergency departments test overdose patients for fentanyl, along with the testing’s costs, risks, benefits, and effects on privacy and care.
After the study, HHS would guide hospitals on routine fentanyl testing, clinicians’ knowledge of drug tests, and possible effects on future overdoses and health.
Argument forThe study could help hospitals make better-informed testing decisions by comparing costs, patient risks, privacy concerns, and possible health effects.
Argument againstPatients may continue facing inconsistent fentanyl testing because the bill requires research and guidance, not hospitals to adopt routine testing or standardize current practices.
More detail
The Secretary of Health and Human Services would complete a study of fentanyl testing in hospital emergency departments. The study would cover testing for fentanyl when a patient is experiencing an overdose, including testing alongside other drugs. The study would examine testing frequency, costs, patient benefits and risks, privacy and health-information confidentiality, and the patient-physician relationship. HHS would complete the study no later than one year after the Act is enacted.
The Secretary of Health and Human Services would issue guidance based on the study’s results. The guidance would address routine fentanyl testing for overdose patients, clinicians’ awareness of tested substances, and possible effects on future overdoses and overall health. The guidance would address whether emergency departments should use fentanyl testing routinely. It would also explain how hospitals can help clinicians know which substances their regular drug tests screen for, whether or not those tests include fentanyl. HHS would issue the guidance no later than six months after completing the study.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2026
- Sep 16Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 625.Latest
- Sep 15Mr. Guthrie moved to suspend the rules and pass the bill.
- Sep 15Considered under suspension of the rules. (consideration: CR H5673-5674)
- Sep 15DEBATE - The House proceeded with forty minutes of debate on H.R. 2004.
- Sep 15Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H5673)Passed House
- Sep 15Motion to reconsider laid on the table Agreed to without objection.
- Sep 14Reported by the Committee on Energy and Commerce. H. Rept. 119-817.
- Sep 14Placed on the Union Calendar, Calendar No. 716.
- Jul 21Committee Consideration and Mark-up Session Held
- Jul 21Ordered to be Reported by the Yeas and Nays: 46 - 0.
- Jul 20Committee Consideration and Mark-up Session Held
- Jun 25Subcommittee Consideration and Mark-up Session Held
- Jun 25Forwarded by Subcommittee to Full Committee by Voice Vote.
- 2025
- Mar 10Introduced in House
- Mar 10Referred to the Subcommittee on Health.
- Mar 10Referred to the House Committee on Energy and Commerce.Introduced
HealthcareConsumer ProtectionAI & Privacy